Message from the CEO to MediciNova Shareholders

Core Insights - The recent study published in the Journal of Atherosclerosis and Thrombosis highlights a novel mechanism by which MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages, crucial for combating atherosclerosis and cardiovascular disease [1][2] - MN-001 shows potential in addressing multiple metabolic disorders, including hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes (T2DM), due to its multi-modal activity and strong safety profile [2][3] Clinical Progress and Future Steps - Patient enrollment for the Phase 2 trial (MN-001-NATG-202) in patients with hypertriglyceridemia and NAFLD due to T2DM has been completed, with top-line results expected by summer 2026 [3] - The combination of newly published mechanistic findings and upcoming trial results will guide the advancement of MN-001 as a potential first-in-class therapy for metabolic and cardiovascular diseases [3] Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases, with a strong pipeline including MN-166 (ibudilast) and MN-001 (tipelukast) [4]